MA-VALAMIS
24.9.2020 10:02:15 CEST | Business Wire | Press release
Valamis , the global leader in digital learning technologies and workforce development, published results from the “Global Survey on the State of Learning & Development (L&D) in the Workplace Report ,” which includes over 3000 people across more than 20 industries were surveyed from entry-level to C-Suite executives in organizations from Finland, France, Germany, Netherlands, Sweden, the US, and the UK.
Valamis conducted its 2nd annual “Global Survey on the State of Learning & Development (L&D) in the Workplace Report”, collecting insight into the shifting global priorities, challenges, behaviors, attitudes, and technologies in use for corporate learning and development, with additional research into the impact of COVID-19.
The importance of learning & development in the workforce
Findings from the survey show that roughly 93% of respondents globally believe updating knowledge and skills are important to an organization’s success and more than 50% of executives and the C-Suite value skills development as extremely important to an organization’s future success. Although the importance of learning and development has been recognized in every country surveyed, over 74% of respondents believe their organizations are actively encouraging the workforce to develop their skills and nearly 56% of respondents had a dedicated person or team responsible for learning and development at their organization.
Time to learn
Despite the globally acknowledged importance of learning and development, for the second consecutive year conducting the survey, the biggest challenge plaguing learning and development within organizations is a lack of time or perceived time affluence with regards to learning. 48% of respondents globally denoted a lack of time as the biggest challenge for learning and development. Interestingly, survey participants at the executive and C-suite level note that they use their digital learning environment the most frequently (Nearly 30% using it every day) of all survey participants.
Tools in place for corporate learning
25% of respondents specify not having the right tools in place as one of the top three challenges for learning & development. Approximately 15% of respondents demarcate that their organization does not have a digital learning environment in place at their organization, and the Netherlands has the highest percentage of respondents of all the countries surveyed that specify they have a Learning Management System (LMS) (24%) or Learning Experience Platform (LXP or LEP) (20%) in place, whereas the United States (28%), United Kingdom (29%), and Germany (28%) have the highest percentages of respondents relying on online courses or Massive Open Online Courses (MOOCs). Finland has the highest number of respondents (18%) that suggest their organization has no digital learning tools in place.
COVID-19 & L&D
Approximately 70% of executives within the global survey express they value digital learning and development more as a result of COVID-19, and over 67% of all global participants in the survey believe digital learning and development can help minimize the effects of shocks and stresses of future events.
“2020 has been a challenging year for many organizations and individuals worldwide. Our global survey on the state of learning and development highlights an internationally growing acknowledgment from the C-suite that L&D is critical to the success of their organizations, and with the right tools in place organizations can adapt and reskill in the face of unforeseen events,” said Janne Hietala, Chief Visionary Officer, Valamis.
Download the report here
.
*Please note the survey results are in English
About Valamis
Valamis is a digital learning company specializing in workforce development, and the developer of Valamis - Learning Experience Platform. Valamis' customers are large organizations spanning all industries—predominantly finance and insurance, complex manufacturing, and professional services. Headquartered in Joensuu, Finland, Valamis operates internationally with offices in the US, the UK, Germany, the Netherlands, Russia, and India.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200924005041/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fujirebio and Sysmex Begin Sales Collaboration for Dementia Testing5.2.2026 07:30:00 CET | Press release
Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa; “Fujirebio”), a consolidated subsidiary of H.U. Group Holdings, Inc. (HQ: Minato-ku, Tokyo; Chairman, President and Group CEO: Shigekazu Takeuchi) and Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano, “Sysmex”) have agreed on a sales collaboration for dementia testing. This agreement follows continued discussions based on the Basic Agreement on Business Collaboration in the Field of Immunoassay concluded in October 2023.1 Sysmex will exclusively sell Fujirebio's fully automated Lumipulse® immunoassay systems and dementia-related reagents ("the Products") in regions and countries mutually agreed upon by both companies. Going forward, Fujirebio and Sysmex will collaborate to meet the growing testing needs accompanying the wider adoption of therapeutic drugs and will gradually expand the countries where the Products are sold. Since entering into the Basic Agreement on Business Collaboration in Octob
Invivoscribe® Launches LeukoStrat® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide5.2.2026 06:30:00 CET | Press release
Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat®KMT2A + MRD Assay and Software to its industry-leading oncology portfolio. The assay leverages digital PCR (dPCR) to support both screening and precise longitudinal MRD monitoring for KMT2A rearrangements in acute myeloid leukemia (AML) subjects. This quantitative test is currently available for research use in clinical trials and as a stand-alone kit for purchase by our global customers, and will soon be available as a service in our regional LabPMM® laboratories worldwide. The assay is available to detect key AML-associated KMT2A rearrangements, which account for the vast majority of KMT2A fusion partners in AML1 and those most commonly targeted in menin-inhibitor clinical development programs. Later this year, the assay will be enhanced with four additional KMT2A rearrangements which are frequently found in acute lymphocytic leukemia (ALL), expan
VeriSilicon Enhanced ISP8200-FS Series IP Achieves ASIL B Functional Safety Certification5.2.2026 01:00:00 CET | Press release
Enabling Next-Generation High-Performance Automotive Camera Systems VeriSilicon (688521.SH) today announced its latest enhanced versions of Image Signal Processing (ISP) IP ISP8200-FS series, ISP8200-ES and ISP8200L-ES, featuring improved performance and energy efficiency to better support complex automotive camera systems. These enhanced IPs have successfully achieved ISO 26262 ASIL B functional safety certifications issued by TÜV NORD, an international inspection and certification institution, further validating their suitability and reliability for ADAS and autonomous driving applications. The latest enhanced ISP8200-FS series IP can operate at up to 1.2 GHz and support data processing from up to 16 image sensors. It significantly improves the performance of multi-camera scheduling, enabling flexible data-access capabilities and efficient hardware pipeline utilization for automotive camera systems. The enhanced series IP integrates image processing technologies including Color Noise
Kinaxis Inc. to Host Fourth Quarter 2025 Financial Results Conference Call on March 5, 20264.2.2026 22:30:00 CET | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced that it has scheduled its conference call to discuss the financial results for its fourth quarter and year ended December 31, 2025. The call will be hosted on Thursday, March 5 at 8:30 a.m. Eastern Time by Razat Gaurav, chief executive officer, and Blaine Fitzgerald, chief financial officer, followed by a question and answer period. The Company will report its financial results for the fourth quarter and year after the close of markets on Wednesday, March 4, 2026. CONFERENCE CALL DETAILS DATE: Thursday, March 5, 2026 TIME: 8:30 a.m. Eastern Time WEBCAST: https://events.q4inc.com/attendee/567578009 (available for three months) About Kinaxis Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that
Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota4.2.2026 22:30:00 CET | Press release
Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. The policy went into effect in January 2026 and specifies that ReActiv8 is the only therapy considered medically necessary by the policy when the conditions for coverage are met. “We are pleased that another Blue Cross Blue Shield payer has joined Anthem in making ReActiv8 available to well-selected patients after reviewing the large body of clinical evidence we have built,”said Jason Hannon, CEO of Mainstay Medical. “Patients with intractable chronic low back pain are desperately seeking durable solutions, and ReActiv8 has proven to be a safe and effective solution through six clinical studies with 633 patients treated and 1,950 patient-years of follow-up, including two multi-center, randomized controlled clinical studies. We look forward to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
